Novinky na Forexu

S&P Global Reiterates FY23 Outlook - Update

While reporting financial results for the second quarter on Thursday, data giant S&P Global, Inc. (SPGI) reiterated its earnings, adjusted pro forma earnings and adjusted pro forma revenue growth guidance for the full-year 2023.
RTTNews | Před 839 dny
Reliance Steel Q2 Results Miss Estimates; Guides Q3 Adj EPS In Line With View

Reliance Steel Q2 Results Miss Estimates; Guides Q3 Adj EPS In Line With View

While reporting financial results for the second quarter on Thursday, metals service center company Reliance Steel & Aluminum Co. (RS) said it expects adjusted earnings for the third quarter in a range of $4.90 to $5.10 per share, as the company expects its average selling price per ton sold for the quarter to be down 2 to 5 percent.
RTTNews | Před 839 dny
more news
Euro Drops After ECB Decision

Euro Drops After ECB Decision

As expected, the European Central Bank raised its main refinancing rate by 25 basis points to 4.25 percent from 4 percent. Following the announcement, the euro fell against its major opponents.
RTTNews | Před 839 dny
Bay Street Likely To Open On Firm Note

Bay Street Likely To Open On Firm Note

Canadian shares look headed for a firm start Thursday morning, tracking positive European markets and higher commodity prices.
RTTNews | Před 839 dny
Euro Mixed Ahead Of ECB Decision

Euro Mixed Ahead Of ECB Decision

The European Central Bank will announce interest rate decision at 8:15 am ET Thursday. The ECB is expected to raise the key refi rate by 25 basis points to 4.25 percent from 4 percent.
RTTNews | Před 839 dny
McDonald's Q2 Profit Soars, Results Top Estimates

McDonald's Q2 Profit Soars, Results Top Estimates

Fast-food giant McDonald's Corp. (MCD) reported Wednesday that net income for the second quarter soared to $2.31 billion or $3.15 per share from $1.19 billion or $1.60 per share in the prior-year quarter.
RTTNews | Před 839 dny
Bristol-Myers Squibb Slashes FY23 Outlook As Q2 Results Miss Estimates

Bristol-Myers Squibb Slashes FY23 Outlook As Q2 Results Miss Estimates

While reporting financial results for the second quarter on Thursday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) slashed its adjusted earnings and revenue growth guidance for the full-year 2023, primarily due to lower than expected sales of Revlimid, and to a lesser extent, Pomalyst.
RTTNews | Před 839 dny

Stay up to date!

Add Zprávy to your browser

Extension Picture